RecruitingNCT03971253
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Sponsor
Astellas Pharma Inc
Enrollment
3,000 participants
Start Date
Sep 2, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
Eligibility
Inclusion Criteria1
- All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
Exclusion Criteria1
- Not applicable.
Interventions
DRUGPeficitinib
Oral
Locations(47)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03971253
Related Trials
Plant-Based Diet for Patients With Rheumatoid Arthritis
NCT072683262 locations
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
NCT065996583 locations
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
NCT072774911 location
A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
NCT072347731 location
Dysphagia in Rheumatoid Arthritis
NCT074017322 locations